Business Context and Reporting Period
This Form 8-K Current Report was filed by Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) on September 17, 2021. The report addresses corporate governance changes regarding the Board of Directors ahead of the Company's Annual Meeting of Stockholders scheduled for November 1, 2021.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Director Departure: Patrick LePore informed the Board on September 17, 2021, that he will not stand for re-election. His term expires at the Annual Meeting.
- Director Nomination: The Company nominated Kathryn Penkus Corzo to stand for election to the Board at the Annual Meeting.
Outlook, Commentary, and Risks
Management Commentary: The Company highlighted Ms. Corzo's background as a partner at Takeda Ventures, Inc., and her previous role as Head, Oncology Cell Therapy Development at Takeda Pharmaceuticals Company Limited. The press release regarding these changes is filed as Exhibit 99.1.
Risks and Contingencies: No specific financial risks or contingencies are detailed in this filing. The document notes that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the outcome of the Board election at the Annual Meeting on November 1, 2021.
- Review the full press release (Exhibit 99.1) for additional details on Ms. Corzo's qualifications and the rationale for the Board composition change.
- Confirm the final composition of the Board of Directors following the Annual Meeting.